APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adalimumab Injection

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Adalimumab Injection Industry Growth and Trends Forecast to 2032

22 December 2025110 pages

Choose your research edition.

Industry ResearchAdalimumab Injection Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Adalimumab Injection Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Adalimumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adalimumab Injection Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Adalimumab Injection Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Adalimumab Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Adalimumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Adalimumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adalimumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Adalimumab Injection include Jiangsu Chia Tai-Tianqing Pharmaceutical, Innovent Biologics, Sandoz, Mylan, Hisun Biopharmaceutical, Shanghai Henlius Biotech, Fresenius Kabi, Bio-Thera Solutions, Ltd. and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Adalimumab Injection market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Adalimumab Injection market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Adalimumab Injection market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Adalimumab Injection.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Adalimumab Injection market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Adalimumab Injection Market by Company

Jiangsu Chia Tai-Tianqing Pharmaceutical

Innovent Biologics

Sandoz

Mylan

Hisun Biopharmaceutical

Shanghai Henlius Biotech

Fresenius Kabi

Bio-Thera Solutions, Ltd.

Amgen

AbbVie

Zydus Group

Celltrion

Cadila Pharmaceuticals

Boehringer Ingelheim

Biogen

Adalimumab Injection Segment by Type

40mg/0.8ml

20mg/0.4ml

Adalimumab Injection Segment by Application

Hospitals

Clinics

Others

Adalimumab Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adalimumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adalimumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adalimumab Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Adalimumab Injection manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Adalimumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 40mg/0.8ml Table 2. Major Company of 20mg/0.4ml Table 3. Global Adalimumab Injection Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Adalimumab Injection Sales by Type (2021-2026) & (k units) Table 5. Global Adalimumab Injection Sales Market Share in Volume by Type (2021-2026) Table 6. Global Adalimumab Injection Sales by Type (2021-2026) & (US$ Million) Table 7. Global Adalimumab Injection Sales Market Share in Value by Type (2021-2026) Table 8. Global Adalimumab Injection Price by Type (2021-2026) & (US$/unit) Table 9. Global Adalimumab Injection Sales by Type (2027-2032) & (k units) Table 10. Global Adalimumab Injection Sales Market Share in Volume by Type (2027-2032) Table 11. Global Adalimumab Injection Sales by Type (2027-2032) & (US$ Million) Table 12. Global Adalimumab Injection Sales Market Share in Value by Type (2027-2032) Table 13. Global Adalimumab Injection Price by Type (2027-2032) & (US$/unit) Table 14. North America Adalimumab Injection Sales by Type (2021-2026) & (k units) Table 15. North America Adalimumab Injection Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Adalimumab Injection Sales by Type (2021-2026) & (k units) Table 17. Europe Adalimumab Injection Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Adalimumab Injection Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Adalimumab Injection Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Adalimumab Injection Sales by Type (2021-2026) & (k units) Table 21. Latin America Adalimumab Injection Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Adalimumab Injection Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Adalimumab Injection Sales by Type (2021-2026) & (US$ Million) Table 24. Adalimumab Injection Industry Trends Table 25. Adalimumab Injection Industry Drivers Table 26. Adalimumab Injection Industry Opportunities and Challenges Table 27. Adalimumab Injection Industry Restraints Table 28. Global Adalimumab Injection Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Adalimumab Injection Revenue Market Share by Company (2021-2026) Table 30. Global Adalimumab Injection Sales by Company (2021-2026) & (k units) Table 31. Global Adalimumab Injection Sales Share by Company (2021-2026) Table 32. Global Adalimumab Injection Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Adalimumab Injection Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Adalimumab Injection Major Company Production Sites and Headquarters Table 35. Global Adalimumab Injection Company, Product Type & Application Table 36. Global Adalimumab Injection Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Adalimumab Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Adalimumab Injection Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Adalimumab Injection Sales by Region (2021-2026) & (k units) Table 41. Global Adalimumab Injection Sales Market Share in Volume by Region (2021-2026) Table 42. Global Adalimumab Injection Sales by Region (2021-2026) & (US$ Million) Table 43. Global Adalimumab Injection Sales Market Share in Value by Region (2021-2026) Table 44. Global Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Adalimumab Injection Sales by Region (2027-2032) & (k units) Table 46. Global Adalimumab Injection Sales Market Share in Volume by Region (2027-2032) Table 47. Global Adalimumab Injection Sales by Region (2027-2032) & (US$ Million) Table 48. Global Adalimumab Injection Sales Market Share in Value by Region (2027-2032) Table 49. Global Adalimumab Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Adalimumab Injection Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Adalimumab Injection Sales by Application (2021-2026) & (k units) Table 52. Global Adalimumab Injection Sales Market Share in Volume by Application (2021-2026) Table 53. Global Adalimumab Injection Sales by Application (2021-2026) & (US$ Million) Table 54. Global Adalimumab Injection Sales Market Share in Value by Application (2021-2026) Table 55. Global Adalimumab Injection Price by Application (2021-2026) & (US$/unit) Table 56. Global Adalimumab Injection Sales by Application (2027-2032) & (k units) Table 57. Global Adalimumab Injection Sales Market Share in Volume by Application (2027-2032) Table 58. Global Adalimumab Injection Sales by Application (2027-2032) & (US$ Million) Table 59. Global Adalimumab Injection Sales Market Share in Value by Application (2027-2032) Table 60. Global Adalimumab Injection Price by Application (2027-2032) & (US$/unit) Table 61. North America Adalimumab Injection Sales by Application (2021-2026) & (k units) Table 62. North America Adalimumab Injection Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Adalimumab Injection Sales by Application (2021-2026) & (k units) Table 64. Europe Adalimumab Injection Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Adalimumab Injection Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Adalimumab Injection Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Adalimumab Injection Sales by Application (2021-2026) & (k units) Table 68. Latin America Adalimumab Injection Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Adalimumab Injection Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Adalimumab Injection Sales by Application (2021-2026) & (US$ Million) Table 71. Jiangsu Chia Tai-Tianqing Pharmaceutical Company Information Table 72. Jiangsu Chia Tai-Tianqing Pharmaceutical Business Overview Table 73. Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Product Portfolio Table 75. Jiangsu Chia Tai-Tianqing Pharmaceutical Recent Development Table 76. Innovent Biologics Company Information Table 77. Innovent Biologics Business Overview Table 78. Innovent Biologics Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Innovent Biologics Adalimumab Injection Product Portfolio Table 80. Innovent Biologics Recent Development Table 81. Sandoz Company Information Table 82. Sandoz Business Overview Table 83. Sandoz Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Sandoz Adalimumab Injection Product Portfolio Table 85. Sandoz Recent Development Table 86. Mylan Company Information Table 87. Mylan Business Overview Table 88. Mylan Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Mylan Adalimumab Injection Product Portfolio Table 90. Mylan Recent Development Table 91. Hisun Biopharmaceutical Company Information Table 92. Hisun Biopharmaceutical Business Overview Table 93. Hisun Biopharmaceutical Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Hisun Biopharmaceutical Adalimumab Injection Product Portfolio Table 95. Hisun Biopharmaceutical Recent Development Table 96. Shanghai Henlius Biotech Company Information Table 97. Shanghai Henlius Biotech Business Overview Table 98. Shanghai Henlius Biotech Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Shanghai Henlius Biotech Adalimumab Injection Product Portfolio Table 100. Shanghai Henlius Biotech Recent Development Table 101. Fresenius Kabi Company Information Table 102. Fresenius Kabi Business Overview Table 103. Fresenius Kabi Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Fresenius Kabi Adalimumab Injection Product Portfolio Table 105. Fresenius Kabi Recent Development Table 106. Bio-Thera Solutions, Ltd. Company Information Table 107. Bio-Thera Solutions, Ltd. Business Overview Table 108. Bio-Thera Solutions, Ltd. Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Bio-Thera Solutions, Ltd. Adalimumab Injection Product Portfolio Table 110. Bio-Thera Solutions, Ltd. Recent Development Table 111. Amgen Company Information Table 112. Amgen Business Overview Table 113. Amgen Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Amgen Adalimumab Injection Product Portfolio Table 115. Amgen Recent Development Table 116. AbbVie Company Information Table 117. AbbVie Business Overview Table 118. AbbVie Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. AbbVie Adalimumab Injection Product Portfolio Table 120. AbbVie Recent Development Table 121. Zydus Group Company Information Table 122. Zydus Group Business Overview Table 123. Zydus Group Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Zydus Group Adalimumab Injection Product Portfolio Table 125. Zydus Group Recent Development Table 126. Celltrion Company Information Table 127. Celltrion Business Overview Table 128. Celltrion Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Celltrion Adalimumab Injection Product Portfolio Table 130. Celltrion Recent Development Table 131. Cadila Pharmaceuticals Company Information Table 132. Cadila Pharmaceuticals Business Overview Table 133. Cadila Pharmaceuticals Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Cadila Pharmaceuticals Adalimumab Injection Product Portfolio Table 135. Cadila Pharmaceuticals Recent Development Table 136. Boehringer Ingelheim Company Information Table 137. Boehringer Ingelheim Business Overview Table 138. Boehringer Ingelheim Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. Boehringer Ingelheim Adalimumab Injection Product Portfolio Table 140. Boehringer Ingelheim Recent Development Table 141. Biogen Company Information Table 142. Biogen Business Overview Table 143. Biogen Adalimumab Injection Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Biogen Adalimumab Injection Product Portfolio Table 145. Biogen Recent Development Table 146. North America Adalimumab Injection Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 147. North America Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 148. North America Adalimumab Injection Sales Market Share by Country (2021-2026) Table 149. North America Adalimumab Injection Sales Forecast by Country (2027-2032) & (k units) Table 150. North America Adalimumab Injection Sales Market Share Forecast by Country (2027-2032) Table 151. North America Adalimumab Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. North America Adalimumab Injection Market Size by Country (2021-2026) & (US$ Million) Table 153. North America Adalimumab Injection Market Share by Country (2021-2026) Table 154. North America Adalimumab Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. North America Adalimumab Injection Market Share Forecast by Country (2027-2032) Table 156. Europe Adalimumab Injection Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 157. Europe Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 158. Europe Adalimumab Injection Sales Market Share by Country (2021-2026) Table 159. Europe Adalimumab Injection Sales Forecast by Country (2027-2032) & (k units) Table 160. Europe Adalimumab Injection Sales Market Share Forecast by Country (2027-2032) Table 161. Europe Adalimumab Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Europe Adalimumab Injection Market Size by Country (2021-2026) & (US$ Million) Table 163. Europe Adalimumab Injection Market Share by Country (2021-2026) Table 164. Europe Adalimumab Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Europe Adalimumab Injection Market Share Forecast by Country (2027-2032) Table 166. Asia-Pacific Adalimumab Injection Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 167. Asia-Pacific Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 168. Asia-Pacific Adalimumab Injection Sales Market Share by Country (2021-2026) Table 169. Asia-Pacific Adalimumab Injection Sales Forecast by Country (2027-2032) & (k units) Table 170. Asia-Pacific Adalimumab Injection Sales Market Share Forecast by Country (2027-2032) Table 171. Asia-Pacific Adalimumab Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Asia-Pacific Adalimumab Injection Market Size by Country (2021-2026) & (US$ Million) Table 173. Asia-Pacific Adalimumab Injection Market Share by Country (2021-2026) Table 174. Asia-Pacific Adalimumab Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Asia-Pacific Adalimumab Injection Market Share Forecast by Country (2027-2032) Table 176. Latin America Adalimumab Injection Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 177. Latin America Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 178. Latin America Adalimumab Injection Sales Market Share by Country (2021-2026) Table 179. Latin America Adalimumab Injection Sales Forecast by Country (2027-2032) & (k units) Table 180. Latin America Adalimumab Injection Sales Market Share Forecast by Country (2027-2032) Table 181. Latin America Adalimumab Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. Latin America Adalimumab Injection Market Size by Country (2021-2026) & (US$ Million) Table 183. Latin America Adalimumab Injection Market Share by Country (2021-2026) Table 184. Latin America Adalimumab Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. Latin America Adalimumab Injection Market Share Forecast by Country (2027-2032) Table 186. Middle East and Africa Adalimumab Injection Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 187. Middle East and Africa Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 188. Middle East and Africa Adalimumab Injection Sales Market Share by Country (2021-2026) Table 189. Middle East and Africa Adalimumab Injection Sales Forecast by Country (2027-2032) & (k units) Table 190. Middle East and Africa Adalimumab Injection Sales Market Share Forecast by Country (2027-2032) Table 191. Middle East and Africa Adalimumab Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 192. Middle East and Africa Adalimumab Injection Market Size by Country (2021-2026) & (US$ Million) Table 193. Middle East and Africa Adalimumab Injection Market Share by Country (2021-2026) Table 194. Middle East and Africa Adalimumab Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 195. Middle East and Africa Adalimumab Injection Market Share Forecast by Country (2027-2032) Table 196. Key Raw Materials Table 197. Raw Materials Key Suppliers Table 198. Adalimumab Injection Distributors List Table 199. Adalimumab Injection Customers List Table 200. Research Programs/Design for This Report Table 201. Authors List of This Report Table 202. Secondary Sources Table 203. Primary Sources List of Figures Figure 1. Adalimumab Injection Image Figure 2. Global Adalimumab Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adalimumab Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Adalimumab Injection Sales (2021-2032) & (k units) Figure 5. 40mg/0.8ml Image Figure 6. Global 40mg/0.8ml Sales YoY Growth (2021-2032) & (k units) Figure 7. 20mg/0.4ml Image Figure 8. Global 20mg/0.4ml Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Adalimumab Injection Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Adalimumab Injection Market Share by Type 2025 VS 2032 Figure 11. North America Adalimumab Injection Sales Market Share in Volume by Type in 2025 Figure 12. North America Adalimumab Injection Sales Market Share in Value by Type in 2025 Figure 13. Europe Adalimumab Injection Sales Market Share in Volume by Type in 2025 Figure 14. Europe Adalimumab Injection Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Adalimumab Injection Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Adalimumab Injection Sales Market Share in Value by Type in 2025 Figure 17. Latin America Adalimumab Injection Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Adalimumab Injection Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Adalimumab Injection Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Adalimumab Injection Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Adalimumab Injection Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospitals Image Figure 24. Global Hospitals Sales YoY Growth (2021-2032) & (k units) Figure 25. Clinics Image Figure 26. Global Clinics Sales YoY Growth (2021-2032) & (k units) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 29. Global Adalimumab Injection Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Adalimumab Injection Market Share by Application 2025 VS 2032 Figure 31. North America Adalimumab Injection Sales Market Share in Volume by Application in 2025 Figure 32. North America Adalimumab Injection Sales Market Share in Value by Application in 2025 Figure 33. Europe Adalimumab Injection Sales Market Share in Volume by Application in 2025 Figure 34. Europe Adalimumab Injection Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Adalimumab Injection Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Adalimumab Injection Sales Market Share in Value by Application in 2025 Figure 37. Latin America Adalimumab Injection Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Adalimumab Injection Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Adalimumab Injection Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Adalimumab Injection Sales Market Share in Value by Application in 2025 Figure 41. North America Adalimumab Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 42. North America Adalimumab Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Adalimumab Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Adalimumab Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Adalimumab Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. Europe Adalimumab Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Adalimumab Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Adalimumab Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Adalimumab Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Asia-Pacific Adalimumab Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Adalimumab Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Adalimumab Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Adalimumab Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Latin America Adalimumab Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Adalimumab Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Adalimumab Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Adalimumab Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Middle East and Africa Adalimumab Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Adalimumab Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Adalimumab Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Adalimumab Injection Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Adalimumab Injection Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • 40mg/0.8ml
  • 20mg/0.4ml
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Jiangsu Chia Tai-Tianqing Pharmaceutical
  • Innovent Biologics
  • Sandoz
  • Mylan
  • Hisun Biopharmaceutical
  • Shanghai Henlius Biotech
  • Fresenius Kabi
  • Bio-Thera Solutions, Ltd.
  • Amgen
  • AbbVie
  • Zydus Group
  • Celltrion
  • Cadila Pharmaceuticals
  • Boehringer Ingelheim
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Adalimumab Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Adalimumab Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Adalimumab Injection Market by Type
  6. 1.3.1 40mg/0.8ml
  7. 1.3.2 20mg/0.4ml
  8. 1.4 Global Adalimumab Injection Market Size by Type
  9. 1.4.1 Global Adalimumab Injection Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Adalimumab Injection Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Adalimumab Injection Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Adalimumab Injection Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Adalimumab Injection Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Adalimumab Injection Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Adalimumab Injection Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Adalimumab Injection Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Adalimumab Injection Industry Trends
  2. 2.2 Adalimumab Injection Industry Drivers
  3. 2.3 Adalimumab Injection Industry Opportunities and Challenges
  4. 2.4 Adalimumab Injection Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Adalimumab Injection Revenue (2021-2026)
  2. 3.2 Global Top Players by Adalimumab Injection Sales (2021-2026)
  3. 3.3 Global Top Players by Adalimumab Injection Price (2021-2026)
  4. 3.4 Global Adalimumab Injection Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Adalimumab Injection Major Company Production Sites & Headquarters
  6. 3.6 Global Adalimumab Injection Company, Product Type & Application
  7. 3.7 Global Adalimumab Injection Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Adalimumab Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Adalimumab Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Adalimumab Injection Tier 1, Tier 2, and Tier 3
4 Adalimumab Injection Regional Status and Outlook
  1. 4.1 Global Adalimumab Injection Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Adalimumab Injection Historic Market Size by Region
  3. 4.2.1 Global Adalimumab Injection Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Adalimumab Injection Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Adalimumab Injection Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Adalimumab Injection Forecasted Market Size by Region
  7. 4.3.1 Global Adalimumab Injection Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Adalimumab Injection Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Adalimumab Injection Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Adalimumab Injection by Application
  1. 5.1 Adalimumab Injection Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Adalimumab Injection Market Size by Application
  6. 5.2.1 Global Adalimumab Injection Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Adalimumab Injection Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Adalimumab Injection Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Adalimumab Injection Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Adalimumab Injection Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Adalimumab Injection Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Adalimumab Injection Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Adalimumab Injection Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Jiangsu Chia Tai-Tianqing Pharmaceutical
  2. 6.1.1 Jiangsu Chia Tai-Tianqing Pharmaceutical Company Information
  3. 6.1.2 Jiangsu Chia Tai-Tianqing Pharmaceutical Business Overview
  4. 6.1.3 Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Product Portfolio
  6. 6.1.5 Jiangsu Chia Tai-Tianqing Pharmaceutical Recent Developments
  7. 6.2 Innovent Biologics
  8. 6.2.1 Innovent Biologics Company Information
  9. 6.2.2 Innovent Biologics Business Overview
  10. 6.2.3 Innovent Biologics Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Innovent Biologics Adalimumab Injection Product Portfolio
  12. 6.2.5 Innovent Biologics Recent Developments
  13. 6.3 Sandoz
  14. 6.3.1 Sandoz Company Information
  15. 6.3.2 Sandoz Business Overview
  16. 6.3.3 Sandoz Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Sandoz Adalimumab Injection Product Portfolio
  18. 6.3.5 Sandoz Recent Developments
  19. 6.4 Mylan
  20. 6.4.1 Mylan Company Information
  21. 6.4.2 Mylan Business Overview
  22. 6.4.3 Mylan Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Mylan Adalimumab Injection Product Portfolio
  24. 6.4.5 Mylan Recent Developments
  25. 6.5 Hisun Biopharmaceutical
  26. 6.5.1 Hisun Biopharmaceutical Company Information
  27. 6.5.2 Hisun Biopharmaceutical Business Overview
  28. 6.5.3 Hisun Biopharmaceutical Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Hisun Biopharmaceutical Adalimumab Injection Product Portfolio
  30. 6.5.5 Hisun Biopharmaceutical Recent Developments
  31. 6.6 Shanghai Henlius Biotech
  32. 6.6.1 Shanghai Henlius Biotech Company Information
  33. 6.6.2 Shanghai Henlius Biotech Business Overview
  34. 6.6.3 Shanghai Henlius Biotech Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Shanghai Henlius Biotech Adalimumab Injection Product Portfolio
  36. 6.6.5 Shanghai Henlius Biotech Recent Developments
  37. 6.7 Fresenius Kabi
  38. 6.7.1 Fresenius Kabi Company Information
  39. 6.7.2 Fresenius Kabi Business Overview
  40. 6.7.3 Fresenius Kabi Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Fresenius Kabi Adalimumab Injection Product Portfolio
  42. 6.7.5 Fresenius Kabi Recent Developments
  43. 6.8 Bio-Thera Solutions, Ltd.
  44. 6.8.1 Bio-Thera Solutions, Ltd. Company Information
  45. 6.8.2 Bio-Thera Solutions, Ltd. Business Overview
  46. 6.8.3 Bio-Thera Solutions, Ltd. Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Bio-Thera Solutions, Ltd. Adalimumab Injection Product Portfolio
  48. 6.8.5 Bio-Thera Solutions, Ltd. Recent Developments
  49. 6.9 Amgen
  50. 6.9.1 Amgen Company Information
  51. 6.9.2 Amgen Business Overview
  52. 6.9.3 Amgen Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Amgen Adalimumab Injection Product Portfolio
  54. 6.9.5 Amgen Recent Developments
  55. 6.10 AbbVie
  56. 6.10.1 AbbVie Company Information
  57. 6.10.2 AbbVie Business Overview
  58. 6.10.3 AbbVie Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 AbbVie Adalimumab Injection Product Portfolio
  60. 6.10.5 AbbVie Recent Developments
  61. 6.11 Zydus Group
  62. 6.11.1 Zydus Group Company Information
  63. 6.11.2 Zydus Group Business Overview
  64. 6.11.3 Zydus Group Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Zydus Group Adalimumab Injection Product Portfolio
  66. 6.11.5 Zydus Group Recent Developments
  67. 6.12 Celltrion
  68. 6.12.1 Celltrion Company Information
  69. 6.12.2 Celltrion Business Overview
  70. 6.12.3 Celltrion Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Celltrion Adalimumab Injection Product Portfolio
  72. 6.12.5 Celltrion Recent Developments
  73. 6.13 Cadila Pharmaceuticals
  74. 6.13.1 Cadila Pharmaceuticals Company Information
  75. 6.13.2 Cadila Pharmaceuticals Business Overview
  76. 6.13.3 Cadila Pharmaceuticals Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Cadila Pharmaceuticals Adalimumab Injection Product Portfolio
  78. 6.13.5 Cadila Pharmaceuticals Recent Developments
  79. 6.14 Boehringer Ingelheim
  80. 6.14.1 Boehringer Ingelheim Company Information
  81. 6.14.2 Boehringer Ingelheim Business Overview
  82. 6.14.3 Boehringer Ingelheim Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Boehringer Ingelheim Adalimumab Injection Product Portfolio
  84. 6.14.5 Boehringer Ingelheim Recent Developments
  85. 6.15 Biogen
  86. 6.15.1 Biogen Company Information
  87. 6.15.2 Biogen Business Overview
  88. 6.15.3 Biogen Adalimumab Injection Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Biogen Adalimumab Injection Product Portfolio
  90. 6.15.5 Biogen Recent Developments
7 North America by Country
  1. 7.1 North America Adalimumab Injection Sales by Country
  2. 7.1.1 North America Adalimumab Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Adalimumab Injection Sales by Country (2021-2026)
  4. 7.1.3 North America Adalimumab Injection Sales Forecast by Country (2027-2032)
  5. 7.2 North America Adalimumab Injection Market Size by Country
  6. 7.2.1 North America Adalimumab Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Adalimumab Injection Market Size by Country (2021-2026)
  8. 7.2.3 North America Adalimumab Injection Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Adalimumab Injection Sales by Country
  2. 8.1.1 Europe Adalimumab Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Adalimumab Injection Sales by Country (2021-2026)
  4. 8.1.3 Europe Adalimumab Injection Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Adalimumab Injection Market Size by Country
  6. 8.2.1 Europe Adalimumab Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Adalimumab Injection Market Size by Country (2021-2026)
  8. 8.2.3 Europe Adalimumab Injection Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Adalimumab Injection Sales by Country
  2. 9.1.1 Asia-Pacific Adalimumab Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Adalimumab Injection Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Adalimumab Injection Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Adalimumab Injection Market Size by Country
  6. 9.2.1 Asia-Pacific Adalimumab Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Adalimumab Injection Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Adalimumab Injection Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Adalimumab Injection Sales by Country
  2. 10.1.1 South America Adalimumab Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Adalimumab Injection Sales by Country (2021-2026)
  4. 10.1.3 South America Adalimumab Injection Sales Forecast by Country (2027-2032)
  5. 10.2 South America Adalimumab Injection Market Size by Country
  6. 10.2.1 South America Adalimumab Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Adalimumab Injection Market Size by Country (2021-2026)
  8. 10.2.3 South America Adalimumab Injection Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Adalimumab Injection Sales by Country
  2. 11.1.1 Middle East and Africa Adalimumab Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Adalimumab Injection Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Adalimumab Injection Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Adalimumab Injection Market Size by Country
  6. 11.2.1 Middle East and Africa Adalimumab Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Adalimumab Injection Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Adalimumab Injection Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Adalimumab Injection Value Chain Analysis
  2. 12.1.1 Adalimumab Injection Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Adalimumab Injection Production Mode & Process
  7. 12.2 Adalimumab Injection Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Adalimumab Injection Distributors
  10. 12.2.3 Adalimumab Injection Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst